Gene therapy for hemophilia B represents a groundbreaking advancement in hemophilia treatment, offering hope to thousands who live with this challenging condition.With the FDA’s approval of Hemgenix, developed by CSL Behring, patients now have access to a revolutionary solution that aims to replace the missing clotting factor in their blood with a one-time treatment.